NYSE:NKGN NKGen Biotech (NKGN) Stock Price, News & Analysis $1.20 +0.05 (+4.35%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.12▼$1.2350-Day Range$0.90▼$1.8652-Week Range$0.78▼$12.88Volume269,957 shsAverage Volume2.20 million shsMarket Capitalization$30.92 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get NKGen Biotech alerts: Email Address Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About NKGen Biotech Stock (NYSE:NKGN)NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Read More NKGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NKGN Stock News HeadlinesJuly 19, 2024 | finance.yahoo.comNKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer’s Association International ConferenceJuly 19, 2024 | msn.comWhy NKGen Biotech (NKGN) Stock Is SkyrocketingJuly 26, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.July 18, 2024 | globenewswire.comNKGen Biotech to Present New Positive SNK01 Clinical Trial Biomarker Data at the 2024 Alzheimer's Association International ConferenceJuly 17, 2024 | americanbankingnews.comReviewing Invivyd (NASDAQ:IVVD) & NKGen Biotech (NYSE:NKGN)July 15, 2024 | globenewswire.comNKGen Biotech Appoints Dr. Marco Gottardis to its Board of DirectorsJune 12, 2024 | globenewswire.comNKGen Biotech Presents Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024June 3, 2024 | globenewswire.comNKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024July 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.May 23, 2024 | globenewswire.comNKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 20, 2024 | investorplace.comNKGN Stock Alert: The Alzheimer’s News That Has NKGen Biotech Soaring TodayMay 20, 2024 | investorplace.comNKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring TodayMay 20, 2024 | markets.businessinsider.comNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 20, 2024 | msn.comWhy NKGen Biotech Stock Is Moving Higher MondayMay 20, 2024 | finance.yahoo.comNKGen Biotech’s SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer’s DiseaseMay 20, 2024 | globenewswire.comNKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's DiseaseMay 16, 2024 | globenewswire.comNKGen Biotech Announces Upcoming Presentation on Autologous NK Cell Therapy at the 5th International Cell & Gene Therapy China Summit & ExhibitionApril 29, 2024 | marketwatch.comNKGen Biotech Shares Rise 15% After FDA Clears Application for Parkinson's Disease TherapySee More Headlines Receive NKGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NKGen Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/20/2024Today7/26/2024Next Earnings (Estimated)8/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:NKGN Previous SymbolNYSE:NKGN CUSIPN/A CIK1845459 Webnkgenbiotech.com Phone949-396-6830FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-82,940,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-243.41% Debt Debt-to-Equity RatioN/A Current Ratio0.04 Quick Ratio0.04 Sales & Book Value Annual Sales$80,000.00 Price / Sales386.55 Cash FlowN/A Price / Cash FlowN/A Book Value($2.68) per share Price / Book-0.45Miscellaneous Outstanding Shares25,770,000Free Float20,617,000Market Cap$30.92 million OptionableNot Optionable Beta0.60 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesDr. Paul Y. Song M.D. (Age 58)CEO & Chairman Comp: $36.58MMr. Sangwoo Park (Age 54)Executive Director Comp: $576kMr. James A. Graf (Age 59)Interim CFO Mr. Pierre Gagnon (Age 52)Chief Operating Officer Ms. Yoonmi KangVice President of Technical OperationsDr. Yong Man Kim Ph.D. (Age 59)Chief Scientific Officer Ms. Denise A. Chua CLSMBA, MT (ASCP), Vice President of Investor Relations & Corporate CommunicationsMs. Irene ChangVice President of Human ResourcesMr. Ryan Park C.F.A.SVP of Financial Planning & Analysis and Corporate StrategyMore ExecutivesKey CompetitorsI-MabNASDAQ:IMABKaryopharm TherapeuticsNASDAQ:KPTICellectisNASDAQ:CLLSCytomX TherapeuticsNASDAQ:CTMXOramed PharmaceuticalsNASDAQ:ORMPView All CompetitorsInsiders & InstitutionsSequoia Financial Advisors LLCBought 16,000 shares on 5/1/2024Ownership: 0.070%Paul Y SongBought 75 shares on 12/6/2023Total: $249.00 ($3.32/share)Paul Y SongBought 244 shares on 11/27/2023Total: $702.72 ($2.88/share)Paul Y SongBought 100 shares on 11/21/2023Total: $280.00 ($2.80/share)James A GrafBought 10 shares on 11/20/2023Total: $29.40 ($2.94/share)View All Insider TransactionsView All Institutional Transactions NKGN Stock Analysis - Frequently Asked Questions How have NKGN shares performed this year? NKGen Biotech's stock was trading at $2.75 at the start of the year. Since then, NKGN shares have decreased by 56.4% and is now trading at $1.20. View the best growth stocks for 2024 here. How were NKGen Biotech's earnings last quarter? NKGen Biotech, Inc. (NYSE:NKGN) posted its quarterly earnings results on Monday, May, 20th. The company reported ($0.25) earnings per share (EPS) for the quarter. How do I buy shares of NKGen Biotech? Shares of NKGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSE:NKGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NKGen Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
